Literature DB >> 18239461

Inhibition of cyclin D1 gene transcription by Brg-1.

Mahadev Rao1, Mathew C Casimiro, Michael P Lisanti, Mark D'Amico, Chenguang Wang, L Andrew Shirley, Jennifer E Leader, Manran Liu, Michael Stallcup, Daniel A Engel, Daniel J Murphy, Richard G Pestell.   

Abstract

The evolutionarily conserved SWI-SNF chromatin remodeling complex regulates cellular proliferation. A catalytic subunit, BRG-1, is frequently down regulated, silenced or mutated in malignant cells, however, the mechanism by which BRG-1 may function as a tumor suppressor or block breast cancer cellular proliferation is not understood. The cyclin D1 gene is a collaborative oncogene overexpressed in greater than 50% of human breast cancers. Herein, BRG-1 inhibited DNA synthesis and cyclin D1 expression in human MCF-7 breast cancer epithelial cells. The cyclin D1 promoter AP-1 and CRE sites were required for repression by BRG-1 in promoter assays. BRG-1 deficient cells abolished and siRNA to BRG-1 reduced, formation of the BRG-1 chromatin complex. The endogenous cyclin D1 promoter AP-1 site bound BRG-1. Estradiol treatment of MCF-7 cells induced recruitment of BRG-1 to the endogenous hpS2 gene promoter. Estradiol, which induced cyclin D1 abundance, was associated with a reduction in recruitment of the co-repressors HP1alpha/HDAC1 to the endogenous cyclin D1 promoter AP-1/BRG-1 binding sites. These studies suggest the endogenous cyclin D1 promoter BRG-1 binding site functions as a molecular scaffold in the context of local chromatin upon which coactivators and corepressors are recruited to regulate cyclin D1.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18239461     DOI: 10.4161/cc.7.5.5446

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  11 in total

1.  v-Src Oncogene Induces Trop2 Proteolytic Activation via Cyclin D1.

Authors:  Xiaoming Ju; Xuanmao Jiao; Adam Ertel; Mathew C Casimiro; Gabriele Di Sante; Shengqiong Deng; Zhiping Li; Agnese Di Rocco; Tingting Zhan; Adam Hawkins; Tanya Stoyanova; Sebastiano Andò; Alessandro Fatatis; Michael P Lisanti; Leonard G Gomella; Lucia R Languino; Richard G Pestell
Journal:  Cancer Res       Date:  2016-09-15       Impact factor: 12.701

2.  AP-1 Subunit JUNB Promotes Invasive Phenotypes in Endometriosis.

Authors:  Mike R Wilson; Jake J Reske; Ronald L Chandler
Journal:  Reprod Sci       Date:  2022-05-26       Impact factor: 2.924

3.  Brg-1 mediates the constitutive and fenretinide-induced expression of SPARC in mammary carcinoma cells via its interaction with transcription factor Sp1.

Authors:  Yong Zhong Xu; Mitra Heravi; Thusanth Thuraisingam; Sergio Di Marco; Thierry Muanza; Danuta Radzioch
Journal:  Mol Cancer       Date:  2010-08-05       Impact factor: 27.401

4.  Nerve Growth factor regulation of cyclin D1 in PC12 cells through a p21RAS extracellular signal-regulated kinase pathway requires cooperative interactions between Sp1 and nuclear factor-kappaB.

Authors:  Francesco Marampon; Mathew C Casimiro; Maofu Fu; Michael J Powell; Vladimir M Popov; Jaime Lindsay; Bianca M Zani; Carmela Ciccarelli; Genichi Watanabe; Richard J Lee; Richard G Pestell
Journal:  Mol Biol Cell       Date:  2008-03-26       Impact factor: 4.138

Review 5.  ATP-dependent chromatin remodeling complexes as novel targets for cancer therapy.

Authors:  Kimberly Mayes; Zhijun Qiu; Aiman Alhazmi; Joseph W Landry
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

6.  Overlapping chromatin-remodeling systems collaborate genome wide at dynamic chromatin transitions.

Authors:  Stephanie A Morris; Songjoon Baek; Myong-Hee Sung; Sam John; Malgorzata Wiench; Thomas A Johnson; R Louis Schiltz; Gordon L Hager
Journal:  Nat Struct Mol Biol       Date:  2013-12-08       Impact factor: 15.369

7.  CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary.

Authors:  Yibo Xue; Brian Meehan; Elizabeth Macdonald; Sriram Venneti; Xue Qing D Wang; Leora Witkowski; Petar Jelinic; Tim Kong; Daniel Martinez; Geneviève Morin; Michelle Firlit; Atefeh Abedini; Radia M Johnson; Regina Cencic; Jay Patibandla; Hongbo Chen; Andreas I Papadakis; Aurelie Auguste; Iris de Rink; Ron M Kerkhoven; Nicholas Bertos; Walter H Gotlieb; Blaise A Clarke; Alexandra Leary; Michael Witcher; Marie-Christine Guiot; Jerry Pelletier; Josée Dostie; Morag Park; Alexander R Judkins; Ralf Hass; Douglas A Levine; Janusz Rak; Barbara Vanderhyden; William D Foulkes; Sidong Huang
Journal:  Nat Commun       Date:  2019-02-04       Impact factor: 14.919

8.  The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a.

Authors:  Therese M Becker; Sebastian Haferkamp; Menno K Dijkstra; Lyndee L Scurr; Monika Frausto; Eve Diefenbach; Richard A Scolyer; David N Reisman; Graham J Mann; Richard F Kefford; Helen Rizos
Journal:  Mol Cancer       Date:  2009-01-16       Impact factor: 27.401

9.  Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex.

Authors:  B Giessrigl; W M Schmidt; M Kalipciyan; M Jeitler; M Bilban; M Gollinger; S Krieger; W Jäger; R M Mader; G Krupitza
Journal:  Br J Cancer       Date:  2013-10-29       Impact factor: 7.640

Review 10.  The regulation of β-catenin activity and function in cancer: therapeutic opportunities.

Authors:  Shuang Shang; Fang Hua; Zhuo-Wei Hu
Journal:  Oncotarget       Date:  2017-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.